Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on November 19, 2007

Circulation. 2007
Published online before print November 19, 2007, doi: 10.1161/CIRCULATIONAHA.107.692996
A more recent version of this article appeared on December 4, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
116/23/2726    most recent
CIRCULATIONAHA.107.692996v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raichlin, E.
Right arrow Articles by Kushwaha, S. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raichlin, E.
Right arrow Articles by Kushwaha, S. S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*AZATHIOPRINE
Medline Plus Health Information
*Heart Transplantation
Related Collections
Right arrow CV surgery: transplantation, ventricular assistance, cardiomyopathy
Right arrow Coronary circulation
Right arrow Endothelium/vascular type/nitric oxide

Submitted on January 27, 2007
Accepted on August 28, 2007

Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation

Eugenia Raichlin MD, Jang-Ho Bae MD, Zain Khalpey MD, MRCS, Brooks S. Edwards MD, Walter K. Kremers PhD, Alfredo L. Clavell MD, Richard J. Rodeheffer MD, Robert P. Frantz MD, Charanjit Rihal MD, Amir Lerman MD, and Sudhir S. Kushwaha MD*

From the William J. von Liebig Transplant Center and the Division of Cardiovascular Diseases, Center for Coronary Physiology and Imaging, Mayo Clinic, Rochester, Minn.

* To whom correspondence should be addressed. E-mail: kushwaha.sudhir{at}mayo.edu.

Background—We investigated the potential of conversion to sirolimus (SRL) as a primary immunosuppressant in attenuating cardiac allograft vasculopathy progression.

Methods and Results—Twenty-nine cardiac transplant recipients were converted to SRL 3.8±3.4 years after transplantation with complete calcineurin inhibitor (CNI) withdrawal. Secondary immunosuppressants (azathioprine or mycophenolate) and steroids remained unchanged. Forty patients (controls) 4.8±4.0 years from transplantation were maintained on CNIs. Three-dimensional intravascular ultrasound studies were performed at baseline and 12.1±2.6 months later. Mean plaque (media and intima) volume (PV) and plaque index (PI) (PV/vessel volume percent) increased significantly in the CNI group (1.28±2.86 mm3/mm, P=0.004; and 6±8%, P=0.0001) but not in the SRL group (0.1±1.13 mm3/mm, P=0.63; and 0.1±8%, P=0.94). In patients enrolled within 2 years after transplantation, the increases in PV (0.06±1.06 versus 1.77±1.65 mm3/mm; P=0.0081) and PI (0±9% versus 10±8%; P=0.0145) were smaller in the SRL group (n=11) than in the CNI (n=12) group. In patients enrolled ≥2 years after transplantation, the increase in PI was less in the SRL group compared with the CNI group (0.1±6.5% versus 5±8%; P=0.033), but changes in PV did not differ significantly. Treatment with azathioprine or mycophenolate did not affect PV or PI in either the SRL group (PV: 0.22±0.66 versus 0.05±1.45 mm3/mm, P=0.46; PI: 1.5±6% versus -1.6±8.5%, P=0.29) or the CNI group (PV: 1.42±1.39 versus 1.06±2.28 mm3/mm, P=0.49; PI: 7.8±8.7% versus 4.8±7.3%, P=0.23).

Conclusions—Substituting CNI with SRL as primary immunosuppression attenuates cardiac allograft vasculopathy progression.


Key words: coronary disease • immune system • transplantation




This article has been cited by other articles:


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
R. J. Novick
Immediate Postoperative Care of the Heart Transplant Recipient: Perils and Triumphs
Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2009; 13(2): 95 - 98.
[Abstract] [PDF]


Home page
Eur Heart JHome page
E. Raichlin, A. Prasad, W. K. Kremers, B. S. Edwards, C. S. Rihal, A. Lerman, and S. S. Kushwaha
Sirolimus as primary immunosuppression is associated with improved coronary vasomotor function compared with calcineurin inhibitors in stable cardiac transplant recipients
Eur. Heart J., June 1, 2009; 30(11): 1356 - 1363.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. Raichlin, J.-H. Bae, S. S. Kushwaha, R. J. Lennon, A. Prasad, C. S. Rihal, and A. Lerman
Inflammatory Burden of Cardiac Allograft Coronary Atherosclerotic Plaque Is Associated With Early Recurrent Cellular Rejection and Predicts a Higher Risk of Vasculopathy Progression
J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1279 - 1286.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. D. Patten
Virtual Histology Intravascular Ultrasound: Assessing the Risk of Cardiac Allograft Vasculopathy
J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1287 - 1288.
[Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
D. van de Beek, W. K. Kremers, S. S. Kushwaha, C. G. A. McGregor, and E. F. M. Wijdicks
No Major Neurologic Complications With Sirolimus Use in Heart Transplant Recipients
Mayo Clin. Proc., April 1, 2009; 84(4): 330 - 332.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M. G. Crespo-Leiro and M. Hermida-Prieto
Sirolimus treatment of left ventricular hypertrophy: who, and when?
Eur. Heart J., November 2, 2008; 29(22): 2703 - 2704.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. A. Hunt and F. Haddad
The Changing Face of Heart Transplantation
J. Am. Coll. Cardiol., August 19, 2008; 52(8): 587 - 598.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. H. Mudge Jr
Sirolimus and Cardiac Transplantation: Is It the "Magic Bullet"?
Circulation, December 4, 2007; 116(23): 2666 - 2668.
[Full Text] [PDF]